Heart Disease
Cardioprotective effects of rosiglitazone related to ANG II receptor and p42/44 MAPK
Published in Hematology Week, September 11th, 2006
"Current evidence points to renin-angiotensin system as a key mediator in ischemia-reperfusion injury. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligand, has recently been shown to confer cardioprotection against ischemia-reperfusion in animal models. We sought to examine the expression of type 2 angiotensin (ANG II) receptors during PPAR-gamma-mediated cardioprotection," researchers in the United States report.
B. Molavi and colleagues at the University of Arkansas...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
Source: Hematology Week (2006-09-11)
More Articles from Hematology Week
- Graft-versus-Host Disease
Progenitor cells trapped in bone marrow filters can reduce graft-versus-host disease - Hematology
Hyporesponsiveness of T cell subsets after cardiac surgery is result of altered TH1 cell function - Leukemia
Acute lymphoblastic leukemia poor prognosis predicted by Aven overexpression - Thalassemia Therapy
Deferasirox has efficacy similar to deferoxamine for treatment of transfusional iron overload - Umbilical Cord Blood Transplantation
Unrelated cord blood transplantation successfully treats malignant infantile osteopetrosis - Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia remission is likely when lymphangiogenesis factor is absent - More from this issue of Hematology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
